Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
RIGL | US
-0.11
-0.81%
Healthcare
Biotechnology
30/06/2024
30/08/2024
13.44
13.55
13.80
13.04
Rigel Pharmaceuticals Inc. a biotechnology company engages in discovering developing and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Rezlidhia a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. It also develops Fostamatinib that has conducted phase III clinical trials for the treatment of warm autoimmune hemolytic anemia; has completed FOCUS phase III clinical trial for the treatment of hospitalized high-risk patients COVID-19; and that is in phase II/III clinical trials for the treatment of COVID-19 in hospitalized patients. In addition the company's other clinical programs include interleukin receptor-associated kinase inhibitor program and a receptor-interacting serine/threonine-protein kinase inhibitor program in clinical development with partner Eli Lilly and Company. Further it has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company was incorporated in 1996 and is headquartered in South San Francisco California.
View LessLow Debt to Equity (< 0.25)
Strong Revenue Growth (> 10%)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
60.7%1 month
87.2%3 months
92.0%6 months
77.9%-
-
31.64
-2.02
0.47
-5.02
1.90
-0.10
-7.52M
236.48M
236.48M
-
1.21
-47.90
42.30
-699.05
5.29
3.28
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.93
Range1M
5.27
Range3M
13.11
Rel. volume
0.91
Price X volume
1.34M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Amarin Corporation plc | AMRN | Biotechnology | 0.6255 | 257.19M | 3.18% | n/a | 1.47% |
scPharmaceuticals Inc | SCPH | Biotechnology | 5.09 | 254.65M | 0.99% | n/a | 447.18% |
OBIO | OBIO | Biotechnology | 6.7 | 253.42M | 0.30% | n/a | 0.00% |
2seventy bio Inc | TSVT | Biotechnology | 4.87 | 250.79M | 1.04% | n/a | 107.07% |
Abeona Therapeutics Inc | ABEO | Biotechnology | 5.7 | 246.89M | 2.52% | n/a | 31.63% |
Zentalis Pharmaceuticals LLC | ZNTL | Biotechnology | 3.47 | 246.74M | 6.77% | n/a | 11.51% |
Omeros Corporation | OMER | Biotechnology | 4.21 | 243.96M | 3.44% | n/a | -356.63% |
Cellectis S.A | CLLS | Biotechnology | 2.4 | 240.23M | 0.00% | n/a | 74.14% |
Nektar Therapeutics | NKTR | Biotechnology | 1.28 | 235.62M | 0.79% | n/a | 275.58% |
Trevi Therapeutics Inc | TRVI | Biotechnology | 3.16 | 229.39M | 8.59% | n/a | 1.80% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 15.53 | 251.70M | 1.70% | 9.96 | 15.44% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 53.7 | 152.52M | -0.37% | 8.42 | 71.47% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14.72 | 92.17M | -2.06% | 14.72 | 7.10% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.38 | 76.89M | 5.34% | n/a | 268.43% |
Emmis Communications Corporation | EMMS | Broadcasting - Radio | 4.7 | 57.98M | -1.05% | n/a | 54.59% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 3.68 | 39.85M | -1.12% | n/a | 54.96% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 2.34 | 28.51M | 13.04% | n/a | 16.03% |
ILAG | ILAG | Building Products & Equipment | 1.25 | 22.57M | 6.84% | n/a | 5.48% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 0.6131 | 18.67M | -4.20% | n/a | 204.46% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2495 | 3.93M | 5.94% | n/a | 0.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -5.02 | 0.97 | Cheaper |
Ent. to Revenue | 1.90 | 3,681.29 | Cheaper |
PE Ratio | - | 39.83 | - |
Price to Book | 31.64 | 14.54 | Expensive |
Dividend Yield | - | 2.19 | - |
Std. Deviation (3M) | 92.02 | 76.13 | Riskier |
Debt to Equity | -2.02 | -2.05 | Cheaper |
Debt to Assets | 0.47 | 0.25 | Expensive |
Market Cap | 236.48M | 4.04B | Emerging |